| Trial ID: | L6443 |
| Source ID: | NCT03659461
|
| Associated Drug: |
Sitagliptin
|
| Title: |
Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes Mellitus
|
| Acronym: |
GLP-1
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus|PreDiabetes
|
| Interventions: |
DRUG: Sitagliptin
|
| Outcome Measures: |
Primary: change in blood glucose load response to sitagliptin, change from blood glucose response at 12 weeks, pre-treatment of sitagliptin and post 12-week treatment of sitagliptin|change in blood insulin response to sitagliptin, change from blood insulin response at 12 weeks, pre-treatment of sitagliptin and post 12-week treatment of sitagliptin |
|
| Sponsor/Collaborators: |
Sponsor: National University of Malaysia
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
174
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT
|
| Start Date: |
2017-10-01
|
| Completion Date: |
2020-01-31
|
| Results First Posted: |
|
| Last Update Posted: |
2022-03-15
|
| Locations: |
Hospital Sultan Ismail, Johor Bahru, Johor, 81100, Malaysia
|
| URL: |
https://clinicaltrials.gov/show/NCT03659461
|
